GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT02276612
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 23
- Registration Number
- NCT02275065
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
- Conditions
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 241
- Registration Number
- NCT02258581
- Locations
- 🇮🇹
IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
🇨🇦Liver and Intestinal Research Centre, Vancouver, British Columbia, Canada
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 10
- Registration Number
- NCT02258529
- Locations
- 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸Prarie Lakes Health Care Systems, Inc., Watertown, South Dakota, United States
🇺🇸St. Agnes Hospital, Baltimore, Maryland, United States
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 7
- Registration Number
- NCT02258555
- Locations
- 🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸Cancer Center Central Connecticut, Southington, Connecticut, United States
🇺🇸Lombardi Cancer Center-Georgetown University, Washington, District of Columbia, United States
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2018-08-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 189
- Registration Number
- NCT02254408
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇧🇷Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
🇧🇷Hospital Universitario USP, Sao Paulo, Brazil
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
- Conditions
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT02254421
- Locations
- 🇨🇭
University Clinical Basel, Basel, Switzerland
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 114
- Registration Number
- NCT02251717
Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)
- Conditions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 26
- Registration Number
- NCT02247934
- Locations
- 🇺🇸
University of Colorado Hospital, Denver Health Medical Center, Aurora, Colorado, United States
🇺🇸University of Miami Miller School of Medicine - Schiff Center for Liver Diseases, Miami, Florida, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 226
- Registration Number
- NCT02249182